Table 1.
Pretreatment clinical characteristics and outcome of younger patients with de novo acute myeloid leukemia assigned to the genetic-risk groups according to the 2017 ELN classification
| Characteristic | All patients n=863 | Favorable-risk n=423 | Intermediate-risk n=189 | Adverse-risk n=251 | P-valuea |
|---|---|---|---|---|---|
| Age, years | 0.54 | ||||
| Median | 45 | 44 | 44 | 46 | |
| Range | 17–59 | 17–59 | 17–59 | 17–59 | |
| Sex, n (%) | 0.01 | ||||
| Male | 473 (55) | 226 (53) | 92 (49) | 155 (62) | |
| Female | 390 (45) | 197 (47) | 97 (51) | 96 (38) | |
| Race, n (%) | 0.27 | ||||
| White | 723 (85) | 360 (87) | 154 (82) | 209 (85) | |
| Nonwhite | 124 (15) | 53 (13) | 33 (18) | 38 (15) | |
| Hemoglobin, g/dl | 0.37 | ||||
| Median | 9.2 | 9.2 | 9.4 | 9.1 | |
| Range | 2.3–25.1 | 2.3–25.1 | 2.9–14.4 | 4.6–14.8 | |
| Platelet count, x109/l | 0.07 | ||||
| Median | 53 | 49 | 56 | 58 | |
| Range | 4–648 | 4–648 | 9–445 | 8–341 | |
| WBC count, x109/l | 0.01 | ||||
| Median | 24.3 | 24.2 | 28.6 | 20.7 | |
| Range | 0.4–475.0 | 0.4–475.0 | 0.9–308.8 | 0.6–320.0 | |
| Blood blasts, % | 0.05 | ||||
| Median | 56 | 52 | 62 | 56 | |
| Range | 0–99 | 0–97 | 0–98 | 0–99 | |
| Bone marrow blasts, % | <0.001 | ||||
| Median | 66 | 63 | 74 | 67 | |
| Range | 0–97 | 2–97 | 10–96 | 0–97 | |
| Extramedullary involvement, n (%) | 222 (27) | 127 (31) | 46 (26) | 49 (20) | 0.001 |
| Complete remission, n (%) | 655 (76) | 389 (92) | 145 (77) | 121 (48) | <0.001 |
| Disease-free survival | <0.001 | ||||
| Median, years | 1.3 | 4.7 | 0.8 | 0.7 | |
| % Disease-free at 3 years (95% CI) | 38 (34–42) | 53 (48–57) | 22 (16–29) | 10 (5–16) | |
| Overall survival | <0.001 | ||||
| Median, years | 2.0 | 12.4 | 1.4 | 0.9 | |
| % Alive at 3 years (95% CI) | 44 (40–47) | 64 (59–68) | 31 (25–38) | 19 (14–24) | |
Abbreviations: CI, confidence interval; n, number; ELN, European LeukemiaNet; WBC, white blood cell.
a
P-values for categorical variables are from Fisher’s exact test, P-values for continuous variables are from the Wilcoxon rank sum test and they are comparing the three risk groups: Favorable, Intermediate and Adverse. P-values for the time to event variables are from the log-rank test and they are comparing the three risk groups: Favorable, Intermediate and Adverse.